Inspra Efficacy In Blacks Insufficient For Superiority Claim, Priority Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A superiority claim for Pharmacia’s anti-hypertensive Inspra for increased efficacy in black patients would require replicated efficacy in large placebo-controlled trials, FDA said in review documents.